粒子形状的重要性:非球形粒子及其稳定皮克林乳液对免疫接种效率的影响
Yanan Li1,2,3, Jie Teng1,2,4, Qiuting Chen1,2,5
1State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China.
Small science
|June 18, 2025
概括
非球状颗粒及其皮克林乳液通过改善抗原递送和免疫细胞激活来增强疫苗免疫反应. 这项研究强调了它们在更有效的细胞和幽默免疫力方面的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 使用球形颗粒和皮克林乳液的辅助剂得到了充分的研究.
- 非球形粒子及其皮克林乳液的免疫效应在很大程度上尚未被探索.
- 粒子形状显著影响粒子-细胞相互作用和抗原储存.
研究的目的:
- 合成各种形态和大小的非球形粒子.
- 使用这些非球形粒子稳定皮克林乳液.
- 评估对抗原呈现细胞 (APC) 以及细胞和幽默免疫的免疫效应.
主要方法:
- 非球形粒子的合成.
- 稳定皮克林乳液的稳定性.
- 在体内居住时间和APC激活的评估.
- 对细胞和幽默免疫反应的评估.
主要成果:
- 非球状颗粒增加疫苗停留时间,增强APC激活,增强细胞免疫力.
- 由非球形颗粒稳定的皮克林乳液显示出更好的灵活性和APCs的抗原吸收.
- 在非球形颗粒稳定乳液中观察到增强的APC激活.
结论:
- 非球形粒子及其皮克林乳液与球形粒子相比,具有优越的免疫特性.
- 这些新型辅助剂显著增强细胞和幽默免疫反应.
- 这些发现表明了疫苗辅助剂开发的有希望的新方向.
更多相关视频
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
3.8K
06:02Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
Published on: February 23, 2024
790
相关概念视频
The Colloidal State
184
The formation of a colloidal system is exemplified by an aqueous solution containing Cl− ions is introduced to another containing Ag+ ions, resulting in the precipitation of solid AgCl as extremely tiny crystals. Instead of settling out as a filterable precipitate, these crystals remain suspended in the liquid, showcasing a colloidal system.A colloidal system involves colloidal particles within the approximate range of 1 to 1000 nm in at least one dimension, dispersed in a medium called...
184
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
